GO
Loading...

Enter multiple symbols separated by commas

Roche Holding AG

More

  • ZURICH/ LOS ANGELES Jan 12- Roche Holding will acquire a majority stake in molecular and genomic analysis business Foundation Medicine, it said on Monday, signalling its determination to expand in cancer immunotherapy by paying a hefty mark-up on the U.S. company's current price. The deal will help the world's largest maker of cancer drugs push ahead in...

  • Great day for Foundation Medicine: CEO   Monday, 12 Jan 2015 | 7:29 AM ET
    Great day for Foundation Medicine: CEO

    CNBC's Meg Tirrell, and Michael Pellini, Foundation Medicine president & CEO, discuss the benefits of Roche's majority stake in Foundation Medicine.

  • Goldman Sachs: Watch out for energy M&A in 2015 Monday, 12 Jan 2015 | 7:14 AM ET
    A derrick hand removes the the plastic caps off the threaded ends of pipe used in the drilling process in Knox County, Ohio.

    Healthcare M&A looks set to be strong again this year, following deals from Shire and Roche. But Goldman Sachs says energy's a sector to watch too.

  • ZURICH/ LOS ANGELES Jan 12- Roche Holding will acquire a majority stake in molecular and genomic analysis firm Foundation Medicine Inc for up to $1.18 billion, it said on Monday, in a move to bolster the Swiss drugmaker's personalised cancer treatments. The drugmaker said it will tender for about 15.6 million Foundation shares at $50 a share, worth up to about $780...

  • Roche to buy majority stake in Foundation Medicine Monday, 12 Jan 2015 | 1:21 AM ET

    Swiss drug maker Roche plans to acquire a majority stake in Foundation Medicine by buying a combination of outstanding and newly issued shares.

  • Big deals, data kick off JPMorgan health conference Monday, 12 Jan 2015 | 1:04 AM ET

    The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.

  • 23 andMe, co-founded by Anne Wojcicki, the wife of Google co-founder Sergey Brin, will contribute the genome sequencing and data from its Parkinson's disease community. Genentech, a unit of Roche Holding AG, will work to identify potential therapeutics based on that information. There is no cure for Parkinson's, which affects about 1 million people in the United...

  • Europe stocks close mixed after Greece vote fails Monday, 29 Dec 2014 | 10:34 AM ET

    European shares closed mixed on Monday, with Greece struck by renewed political uncertainty after its politicians failed to agree on a new president.

  • Dec 22- The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co's skin cancer drug, more than three months before the scheduled review date. The drug is the second PD-1 inhibitor to be approved by the FDA, the first being Merck& Co Inc's Keytruda in September. The FDA was scheduled to review the drug on March 30.

  • Europe closes mixed; Italian banks, health care weigh Friday, 19 Dec 2014 | 11:31 AM ET

    European shares closed mixed on Friday, with Italian banking stocks and the health care sector weighing on wider benchmarks.

  • Dec 12- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers. The deal stirred speculation that developers such as Cempra could also be takeover targets. I know a lot of other biotechs are, " Cempra Chief Executive Prabha Fernandes said in an...

  • Bad flu season: A prescription for growth? Wednesday, 10 Dec 2014 | 8:16 AM ET
    A mam receives an influenza shot from a Nurse Practitioner in the MinuteClinic at the CVS/pharmacy.

    The health-care sector tends to outperform the overall market during flu season. Who else stands to gain?

  • Fighting kids' cancer, one voucher at a time Friday, 21 Nov 2014 | 10:03 AM ET
    Jacob with his parents Mike Froman and Nancy Goodman, and brother Ben (Spring 2008)

    There are few new cancer drugs to treat kids, and not much research is being done.

  • German Merck, Pfizer in immunotherapy deal Monday, 17 Nov 2014 | 5:47 AM ET

    Germany's Merck KGaA said Monday it struck an alliance over cancer immunotherapy drugs with Pfizer, triggering an upfront payment of $850 million by the U.S. drugmaker.

  • US pulls approval for these Nexium, Valcyte generics Thursday, 6 Nov 2014 | 9:47 AM ET

    The U.S. FDA has revoked a tentative approval for India's Ranbaxy to make a cheap copy of AstraZeneca's heartburn drug Nexium.

  • Alibaba’s market value surpasses Wal-Mart Tuesday, 28 Oct 2014 | 8:27 PM ET
    An employee walks past the Alibaba logo during a media tour organized by government officials at the company’s headquarters outside of Hangzhou, Zhejiang province, China.

    Alibaba muscled ahead of Wal-Mart by one important measure, when its market valuation surpassed the retailer by revenues. The Financial Times reports.

  • Drugmakers double down on Ebola vaccines, treatments Monday, 27 Oct 2014 | 7:31 AM ET
    People participate in a march, organized by New York’s West African community, to end Ebola, Oct. 24, 2014, in New York.

    Drugmakers are racing to develop vaccines and drugs to address Ebola, betting that governments and aid groups will foot the bill.

  • Europe closes off lows, Greek bond yields near 9% Thursday, 16 Oct 2014 | 11:49 AM ET

    European shares closed lower on Thursday after trimming losses, tracking U.S. markets which partially recovered after visiting correction territory.

  • Roche sales beat forecasts, confirms outlook Thursday, 16 Oct 2014 | 3:34 AM ET

    Roche reported third quarter sales of 11.78 billion Swiss francs ($12.29 billion) on Thursday, above analysts' forecasts of 11.58 billion Swiss francs in a Reuters poll.

  • We're not looking at mega-mergers: Roche CEO   Thursday, 16 Oct 2014 | 2:45 AM ET
    We're not looking at mega-mergers: Roche CEO

    Severin Schwan, CEO of Roche Group, says the company's "fundamental strategy" has not changed and is looking at "targeted" M&A deals.